Skip to main content

Tiludronate Dosage

Applies to the following strengths: 200 mg

Usual Adult Dose for Paget's Disease

-400 mg orally once a day for a period of 3 months

-Refer to administration advice for details on how to take this drug.
-Following therapy, allow an interval of 3 months to assess response; specific data regarding retreatment are limited.

-Treatment in patients with Paget's disease of bone(osteitis deformans) with a level of serum alkaline phosphatase (SAP) of at least twice the upper limit of normal, or who are symptomatic, or who are at risk for future disease complications.

Renal Dose Adjustments

Mild to moderate renal dysfunction (CrCl 30 mL/min or greater): Data not available
Severe renal dysfunction (CrCl less than 30 mL/min): Not recommended.

Liver Dose Adjustments

No adjustment recommended.


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-This drug should be taken with 6 to 8 ounces of plain water only, for a period of 3 months.
-This drug should not be taken within 2 hours of food.
-Beverages other than plain water (including mineral water), food, and some medications are likely to reduce the absorption of this drug.
-Patients should not lie down for at least 30 minutes after taking this drug.
-Appropriate supervision is recommended in patients who cannot comply with dosing instructions due to mental or physical disability.
-Calcium, mineral supplements, aspirin, and indomethacin should be taken at least 2 hours before or two hours after this drug.
-Aluminum or magnesium containing antacids, if needed, should be taken at least two hours after taking this drug.
-Adequate vitamin D and calcium intake should be maintained.

-Metabolic: Serum calcium and symptoms of hypocalcemia

Patient advice:
-Report any side effect that bothers or that does not go away.
-Failure to follow administration instructions for this drug may increase the risk of esophageal adverse reactions.
-Discontinue this drug and seek medical attention if dysphagia, odynophagia, retrosternal pain or new or worsening heartburn develop.

More about tiludronate

Patient resources

Other brands

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.